Comparative Pharmacology
Head-to-head clinical analysis: DESMODA versus PITRESSIN TANNATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESMODA versus PITRESSIN TANNATE.
DESMODA vs PITRESSIN TANNATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone, ADH) that acts on V2 receptors in renal collecting ducts, increasing water reabsorption and reducing urine output. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor stimulation on endothelial cells.
Pitressin Tannate is a synthetic form of vasopressin (antidiuretic hormone) that acts on V2 receptors in the renal collecting ducts to increase water reabsorption, and on V1 receptors to cause vasoconstriction.
10 mg orally once daily
0.5-1 mL (5-10 units) intramuscularly or subcutaneously every 24-48 hours as needed for diabetes insipidus.
None Documented
None Documented
Terminal half-life: 8-12 hours; extended in renal impairment (up to 24 hours).
Terminal elimination half-life approximately 15 minutes (range 10–20 minutes). Clinically, due to rapid clearance, effects are short-lived; continuous infusion or depot formulations are required for sustained effect.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Primarily renal: >95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal elimination negligible (<5%).
Category C
Category C
Antidiuretic Hormone Analog
Antidiuretic Hormone Analog